{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:18:05Z","timestamp":1785806285675,"version":"3.56.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"DOI":"10.1093\/humrep\/dei072","type":"journal-article","created":{"date-parts":[[2005,5,20]],"date-time":"2005-05-20T00:24:27Z","timestamp":1116548667000},"page":"2457-2462","source":"Crossref","is-referenced-by-count":85,"title":["High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception"],"prefix":"10.1093","volume":"20","author":[{"given":"Lourdes","family":"Ib\u00e1\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"de Zegher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,5,19]]},"reference":[{"key":"key\n\t\t\t\t20171011142020_R1","doi-asserted-by":"crossref","unstructured":"Asunci\u00f3n M, Calvo RM, San Millan JL, Sancho J, Avila S and Escobar-Morreale H (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab85, 2434\u20132438.","DOI":"10.1210\/jc.85.7.2434"},{"key":"key\n\t\t\t\t20171011142020_R2","doi-asserted-by":"crossref","unstructured":"Baumann EE and Rosenfield RL (2002) Polycystic ovary syndrome in adolescence. Endocrinologist12, 333\u2013348.","DOI":"10.1097\/00019616-200207000-00011"},{"key":"key\n\t\t\t\t20171011142020_R3","doi-asserted-by":"crossref","unstructured":"Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O and Blumenfeld Z (2004) Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab89, 2160\u20132165.","DOI":"10.1210\/jc.2003-031096"},{"key":"key\n\t\t\t\t20171011142020_R4","doi-asserted-by":"crossref","unstructured":"Dandona P, Aljada A, Chaudhuri A and Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Inmunol25, 4\u20137.","DOI":"10.1016\/j.it.2003.10.013"},{"key":"key\n\t\t\t\t20171011142020_R5","doi-asserted-by":"crossref","unstructured":"de Leo V, Lanzetta D, D'Antona D, a Marca A and Morgante G (1998) Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab83, 99\u2013102.","DOI":"10.1210\/jcem.83.1.4500"},{"key":"key\n\t\t\t\t20171011142020_R6","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis E, Mitrakou A and Raptis S Tolis G and Duleba AJ (1998) The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab83, 2699\u20132705.","DOI":"10.1210\/jcem.83.8.5041"},{"key":"key\n\t\t\t\t20171011142020_R7","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ and Nestler JE (2003) Controversies in endocrinology. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab88, 1927\u20131932.","DOI":"10.1210\/jc.2002-021528"},{"key":"key\n\t\t\t\t20171011142020_R8","doi-asserted-by":"crossref","unstructured":"Dunaif A and Thomas A (2000) Current concepts in the polycystic ovary syndrome. Annu Rev Med52, 401\u2013419.","DOI":"10.1146\/annurev.med.52.1.401"},{"key":"key\n\t\t\t\t20171011142020_R9","unstructured":"Dunaif A, Scott D, Finegood D, Quintana B and Whitcomb R (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab81, 3299\u20133306."},{"key":"key\n\t\t\t\t20171011142020_R10","doi-asserted-by":"crossref","unstructured":"Elter K, Imir G and Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin addedd to ethynil-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod17, 1729\u20131737.","DOI":"10.1093\/humrep\/17.7.1729"},{"key":"key\n\t\t\t\t20171011142020_R11","doi-asserted-by":"crossref","unstructured":"Expert Committe on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care20, 1183\u20131197.","DOI":"10.2337\/diacare.20.7.1183"},{"key":"key\n\t\t\t\t20171011142020_R12","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Real JM and Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev24, 278\u2013301.","DOI":"10.1210\/er.2002-0010"},{"key":"key\n\t\t\t\t20171011142020_R13","doi-asserted-by":"crossref","unstructured":"Ferriman D and Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab21, 1440\u20131447.","DOI":"10.1210\/jcem-21-11-1440"},{"key":"key\n\t\t\t\t20171011142020_R14","doi-asserted-by":"crossref","unstructured":"Fonseca V, Desouza C, Asnani S and Jialal I (2004) Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev25, 153\u2013175.","DOI":"10.1210\/er.2002-0034"},{"key":"key\n\t\t\t\t20171011142020_R15","doi-asserted-by":"crossref","unstructured":"Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U and Pasquali R (2004) Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol60 (ii), 241\u2013249.","DOI":"10.1111\/j.1365-2265.2004.01973.x"},{"key":"key\n\t\t\t\t20171011142020_R16","doi-asserted-by":"crossref","unstructured":"Goldfine AB and Kahn CR (2003) Adiponectin: linking the fat cell to insulin sensitivity. Lancet362, 1431\u20131432.","DOI":"10.1016\/S0140-6736(03)14727-7"},{"key":"key\n\t\t\t\t20171011142020_R17","doi-asserted-by":"crossref","unstructured":"Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R and Lanzone A (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab89, 2817\u20132823.","DOI":"10.1210\/jc.2003-031158"},{"key":"key\n\t\t\t\t20171011142020_R18","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L and de Zegher F (2003) Flutamide-metformin to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab88, 4720\u20134724.","DOI":"10.1210\/jc.2003-030117"},{"key":"key\n\t\t\t\t20171011142020_R19","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L and de Zegher F (2004a) Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and young women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab89, 1592\u20131597.","DOI":"10.1210\/jc.2003-031281"},{"key":"key\n\t\t\t\t20171011142020_R20","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L and de Zegher F (2004b) Flutamide-Metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod19, 1725\u20131727.","DOI":"10.1093\/humrep\/deh329"},{"key":"key\n\t\t\t\t20171011142020_R21","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L and de Zegher F (2005) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at start and after more than one year of therapy. J Clin Endocrinol Metab90, 39\u201343.","DOI":"10.1210\/jc.2004-1405"},{"key":"key\n\t\t\t\t20171011142020_R22","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Potau N, Zampolli M, Riqu\u00e9 S, Saenger P and Carrascosa A (1997) Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab82, 2283\u20132288.","DOI":"10.1210\/jcem.82.7.4084"},{"key":"key\n\t\t\t\t20171011142020_R23","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, de Zegher F, Francois I and Potau N (1998) Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab83, 3558\u20133662.","DOI":"10.1210\/jcem.83.10.5205"},{"key":"key\n\t\t\t\t20171011142020_R24","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Potau N, Marcos MV and de Zegher F (2000a) Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab85, 3526\u20133530.","DOI":"10.1210\/jc.85.10.3526"},{"key":"key\n\t\t\t\t20171011142020_R25","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Potau N, Marcos MV and de Zegher F (2000b) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in non-obese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab85, 3251\u20133255.","DOI":"10.1210\/jc.85.9.3251"},{"key":"key\n\t\t\t\t20171011142020_R26","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Potau N, Marcos MV and de Zegher F (2001a) Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birthweight effect. Clin Endocrinol55, 667\u2013672.","DOI":"10.1046\/j.1365-2265.2001.01399.x"},{"key":"key\n\t\t\t\t20171011142020_R27","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F and de Zegher F (2001b) Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab86, 3595\u20133598.","DOI":"10.1210\/jcem.86.8.7756"},{"key":"key\n\t\t\t\t20171011142020_R28","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Ferrer A, Ong K, Dunger D and de Zegher F (2002a) Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab87, 2870\u20132874.","DOI":"10.1210\/jcem.87.6.8568"},{"key":"key\n\t\t\t\t20171011142020_R29","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Mir\u00f3 E, Marcos MV and de Zegher F (2002b) Early menarche and subclinical ovarian hyperandrogenism in girls with reduced adult height after low birthweight. J Pediatr Endocrinol Metab15, 431\u2013433.","DOI":"10.1515\/JPEM.2002.15.4.431"},{"key":"key\n\t\t\t\t20171011142020_R30","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV and de Zegher F (2002c) Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab87, 5702\u20135705.","DOI":"10.1210\/jc.2002-020926"},{"key":"key\n\t\t\t\t20171011142020_R31","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Ong K, Ferrer A, Amin R, Dunger D and de Zegher F (2003) Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents and young women with ovarian hyperandrogenism. J Clin Endocrinol Metab88, 2600\u20132606.","DOI":"10.1210\/jc.2002-022002"},{"key":"key\n\t\t\t\t20171011142020_R32","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Marcos MV, Ong K, Dunger D and de Zegher F (2004a) Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin. J Clin Endocrinol Metab89, 4331\u20134337.","DOI":"10.1210\/jc.2004-0463"},{"key":"key\n\t\t\t\t20171011142020_R33","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Cabr\u00e9 S and de Zegher F (2004b) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab89, 4716\u20134720.","DOI":"10.1210\/jc.2004-0047"},{"key":"key\n\t\t\t\t20171011142020_R34","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Ferrer A, Ong K, Amin R, Dunger D and de Zegher F (2004c) Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr144, 23\u201329.","DOI":"10.1016\/j.jpeds.2003.08.015"},{"key":"key\n\t\t\t\t20171011142020_R35","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez L, Jaramillo A, Ferrer A, Zegher F and de Zegher F (2005) Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod in press.","DOI":"10.1093\/humrep\/dei004"},{"key":"key\n\t\t\t\t20171011142020_R36","doi-asserted-by":"crossref","unstructured":"Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM and Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab86, 2453\u20132455.","DOI":"10.1210\/jcem.86.6.7580"},{"key":"key\n\t\t\t\t20171011142020_R37","doi-asserted-by":"crossref","unstructured":"Libby P (2002) Inflammation and atherosclerosis. Nature420, 868\u2013874.","DOI":"10.1038\/nature01323"},{"key":"key\n\t\t\t\t20171011142020_R38","unstructured":"Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E and Muggeo M (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab85, 139\u2013146."},{"key":"key\n\t\t\t\t20171011142020_R39","doi-asserted-by":"crossref","unstructured":"Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M and Tapanainen JS (2003a) Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab88, 4649\u20134654.","DOI":"10.1210\/jc.2002-021688"},{"key":"key\n\t\t\t\t20171011142020_R40","doi-asserted-by":"crossref","unstructured":"Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H and Tapanainen JS (2003b) Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of non-obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab88, 148\u2013156.","DOI":"10.1210\/jc.2002-020997"},{"key":"key\n\t\t\t\t20171011142020_R41","unstructured":"Nestler JE and Jakubowicz DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17\u03b1activity and serum androgens. J Clin Endocrinol Metab82, 4075\u20134079."},{"key":"key\n\t\t\t\t20171011142020_R42","doi-asserted-by":"crossref","unstructured":"New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S and Levine LS (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab56, 320\u2013325.","DOI":"10.1210\/jcem-57-2-320"},{"key":"key\n\t\t\t\t20171011142020_R43","doi-asserted-by":"crossref","unstructured":"Orio P Jr F, Palomba S, Cascella T, DI Biase S, Manguso F, Tauchmanova\u2019 L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A and Lombardi G (2005) The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J Clin Endocrinol Metab90, 2\u20135.","DOI":"10.1210\/jc.2004-0628"},{"key":"key\n\t\t\t\t20171011142020_R44","doi-asserted-by":"crossref","unstructured":"Palep-Singh M, Mook K, Barth J and Balen A (2004) An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care30, 163\u2013165.","DOI":"10.1783\/1471189041261636"},{"key":"key\n\t\t\t\t20171011142020_R45","unstructured":"Sakkal-Alkaddour H, Zhang L, Yang X, Chang YT, Kappy M and Slover RS (1996) Studies of 3\u03b2-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated D5-steroid levels. J Clin Endocrinol Metab81, 3961\u20133965."},{"key":"key\n\t\t\t\t20171011142020_R46","doi-asserted-by":"crossref","unstructured":"Sj\u00f6holm A and Nystr\u00f6m T (2005) Endothelial inflammation in insulin resistance. Lancet365, 610\u2013612.","DOI":"10.1016\/S0140-6736(05)17912-4"},{"key":"key\n\t\t\t\t20171011142020_R47","doi-asserted-by":"crossref","unstructured":"Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T and Duman C (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab89, 5592\u20135596.","DOI":"10.1210\/jc.2004-0751"},{"key":"key\n\t\t\t\t20171011142020_R48","unstructured":"Vidal-Puig A and Moller DE (1997) Insulin resistance: classification, prevalence, clinical manifestations, and diagnosis. In Azziz R, Nestler JE, and Dewailly D (eds) Androgen Excess Disorders in Women. Lippincott\u2013Raven Publishers, Philadelphia, USA, pp. 227\u2013236."},{"key":"key\n\t\t\t\t20171011142020_R49","doi-asserted-by":"crossref","unstructured":"Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL and Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest112, 1796\u20131808.","DOI":"10.1172\/JCI200319246"},{"key":"key\n\t\t\t\t20171011142020_R50","doi-asserted-by":"crossref","unstructured":"Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA and Chen H (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest112, 1821\u20131830.","DOI":"10.1172\/JCI200319451"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/20\/9\/2457\/6953696\/dei072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T11:13:10Z","timestamp":1586257990000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/humrep\/article\/20\/9\/2457\/2356733\/High-neutrophil-count-in-girls-and-women-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,19]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2005,5,19]]},"published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dei072","relation":{},"ISSN":["1460-2350","0268-1161"],"issn-type":[{"value":"1460-2350","type":"electronic"},{"value":"0268-1161","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,9]]},"published":{"date-parts":[[2005,5,19]]}}}